Article

Greater Risk of Lung Cancer Found in Smokers with Pneumonia

Rate of lung cancer significantly higher in patients with upper lobe pneumonia.

A recent study suggests that screening heavy smokers hospitalized for pneumonia could improve the early diagnosis of lung cancer.

Lung cancer, which is the leading cause of cancer death in the United States, shows no symptoms in the early stages. Once symptoms appear, the cancer is often at an aggressive and progressed stage.

This makes the disease difficult to catch in early its early stages. Today, 85% of all lung cancer is caused by smoking.

Only 15% of patients are diagnosed in the early stages and just 17% of patients have a 5-year survival rate.

The results of the study, published in the American Journal of Medicine, proposed that if heavy smokers hospitalized for pneumonia are screened, it could reduce mortality rates.

Investigators studied the files of 381 smokers with pneumonia between 2007 and 2011 at Rabin Medical Center.

They found that 9% (31 out of 381) of smokers with pneumonia were diagnosed with lung cancer within a year of hospitalization. The rate of lung cancer was significantly higher in those with upper lobe pneumonia (23.8%). In 75.8% of these patients, lung cancer was found in the lobe.

"Considering that only 0.5 to 1% of smokers without pneumonia have a chance of being diagnosed with lung cancer every year, the fact that 9% of our study group developed lung cancer is alarming," said lead researcher Daniel Shepshelovich, MD.

Currently chest X-rays and cytology are methods used for lung cancer diagnosis. Although they are able to sometimes find the cancerous tumors, it does not change the mortality rates.

"In other words, people are aware that they have cancer for longer periods of time, but do not recover,” Dr. Shepshelovich said. “This is not a solution.”

Dr. Shepshelovich strongly believes that heavy smokers who are admitted to the hospital with pneumonia should be considered for a chest-computer tomography.

"Only 15% of lung cancer cases are detected at an early stage,” he said. “We want to increase that number in order to reduce mortality or, at the very least, extend lives."

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards